...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular cytogenetics >Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
【24h】

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

机译：miR-181c在伊马替尼耐药的慢性粒细胞白血病中的下调

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4 imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. Some miR-181c target genes such as PBX3, HSP90B1, NMT2 and RAD21 have been associated with drug response.
机译：在不同类型的癌症中，已经揭示了microRNA改变与进展和治疗结果之间的关系。为了找到参与伊马替尼反应的miRNA，我们进行了miRNA芯片分析，然后通过RT-qPCR验证了来自9名CML患者（包括4名伊马替尼耐药和5名伊马替尼治疗患者）的9种可用的诊断性骨髓活检。当将伊马替尼耐药组与伊马替尼应答者进行比较时，仅发现一种差异表达的miRNA，miR-181c。通过qRT-PCR证实了伊马替尼耐药组和伊马替尼应答组中miR-181c的显着下调。一些miR-181c靶基因，例如PBX3，HSP90B1，NMT2和RAD21与药物反应有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号